Dermira is a medical dermatology company committed to bringing science and innovation to patients.

Innovation and product development in the field of medical dermatology has lagged behind other disease areas and, until recently, most companies in the space have primarily focused on reformulations of existing treatments. While there have been significant treatment developments for a limited number of conditions such as atopic dermatitis, the standard of care for most dermatologic conditions has not changed in several decades.

As a result, new treatment options for dermatologic conditions are needed to help address the needs of, and deliver value to, patients and healthcare professionals.

Our focused approach to product development seeks to improve the lives of patients suffering from chronic skin conditions. Angela Boyd, Vice President of Patient Value and Professional Relations, describes how we’re striving to make a meaningful difference.

Watch Video >

We are re-envisioning medical dermatology.

Dermira is dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology.

We are answering patient needs across the $21 billion medical dermatology market by going beyond incremental improvements. Instead, we’re focused on the development of game-changing therapies that elevate existing standards of care for people living with chronic skin diseases.

Our portfolio includes our first approved medication for the treatment of primary axillary hyperhidrosis, as well as product candidates for the treatment of atopic dermatitis and other indications.

Primary Axillary Hyperhidrosis

Excessive underarm sweating can cause emotional, social and physical impairment, and impacts the lives of nearly 10 million Americans.1

Discover More >

Atopic Dermatitis

Atopic dermatitis is the most common and severe form of eczema, a chronic inflammatory condition. The moderate-to-severe form of atopic dermatitis affects approximately 10 million people in the U.S. and can present as early as childhood and continue into adulthood.2-7

Discover More >

Helpful Resources

Many leading patient and professional organizations are doing important work for patients living with chronic skin conditions and the healthcare professionals who care for them.

Learn More >
  • 1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743-749.
  • 2. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139:583-590.
  • 3. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25:107-114.
  • 4. United States Census Bureau. U.S. and World Population Clock. Available at: https://www.census.gov/popclock/. Accessed December 31, 2018.
  • 5. Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, et al. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol. 2018;121:729-734.
  • 6. National Eczema Association. Available at: https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/ Accessed July 26, 2017.
  • 7. Silverberg & Hanifin 2013; Thomson Reuters IPD (Incidence & Prevalence Database), Accessed on August 4, 2017.